Back to Search
Start Over
Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab
- Source :
- Acta Oncologica. 59:1058-1063
- Publication Year :
- 2020
- Publisher :
- Informa UK Limited, 2020.
-
Abstract
- Objectives: We retrospectively analysed patients with advanced non-small-cell lung cancer (NSCLC) harbouring high PD-L1 expression (>50%) and treated with front-line pembrolizumab, comparing outcom...
- Subjects :
- Adult
Male
Oncology
medicine.medical_specialty
Lung Neoplasms
Pembrolizumab
Antibodies, Monoclonal, Humanized
Severity of Illness Index
B7-H1 Antigen
030218 nuclear medicine & medical imaging
Young Adult
03 medical and health sciences
Antineoplastic Agents, Immunological
0302 clinical medicine
Carcinoma, Non-Small-Cell Lung
PD-L1
Internal medicine
medicine
Humans
Radiology, Nuclear Medicine and imaging
Lung cancer
Lung
Aged
Retrospective Studies
Aged, 80 and over
Performance status
biology
business.industry
digestive, oral, and skin physiology
Front line
Hematology
General Medicine
Middle Aged
Prognosis
medicine.disease
Progression-Free Survival
humanities
respiratory tract diseases
Europe
Drug Resistance, Neoplasm
030220 oncology & carcinogenesis
biology.protein
Female
Non small cell
business
Subjects
Details
- ISSN :
- 1651226X and 0284186X
- Volume :
- 59
- Database :
- OpenAIRE
- Journal :
- Acta Oncologica
- Accession number :
- edsair.doi.dedup.....ada39f2c4b0e1f72520b3cf285adcb71